The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / November / Viridian Reports Positive Phase 1 Results for VRDN008
Research & Innovations Latest News

Viridian Reports Positive Phase 1 Results for VRDN-008

Investigational therapy demonstrates sustained IgG reductions for up to eight weeks, supporting less frequent dosing for autoimmune diseases

11/18/2026 2 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll
5 Key Takeaways
  • 1

    In a Phase 1 study of healthy volunteers, subcutaneous VRDN-008 produced a peak IgG reduction of 74%, maintained for up to 8 weeks.

  • 2

    VRDN-008 had a reported half-life of 15 to 18 days, approximately six times longer than first-generation Fc fragments.

  • 3

    The therapy was generally well tolerated, with no serious adverse events or dose-limiting toxicities and no reductions in albumin or LDL cholesterol.

  • 4

    Viridian plans to begin a pivotal trial in myasthenia gravis in mid-2027, subject to regulatory feedback, evaluating dosing every 4 and 8 weeks.

  • 5

    VRDN-008 has not demonstrated clinical benefit in thyroid eye disease, and Viridian has not announced a TED-specific development program for the drug.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: